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as a ﬁrst-line therapy for VAP. Clinical Cure, utilization data, incidence of adverse 
events, days on mechanical ventilation (MV), ICU days, and LOS in hospital, were 
estimated by combining data from two randomized multicenters, non-inferiority clini-
cal trials of doripenem. Only direct medical costs were considered. Unitary costs of 
MV, ICU, ward days and drugs costs were obtained from the IMSS. The primary 
outcomes were total costs and incremental cost per clinical cure. Sensitivity analyses 
included one-way scenarios and probabilistic analyses (SPA). Results are shown in 
percents, while costs are expressed in Dollars. RESULTS: Doripenem was the least 
expensive treatment in patients with VAP, and in average generated savings of 
$3,374.47/treated patient vs imipenem and $985.04/treated patient vs PT. Doripenem 
dominated PT by being less costly with better clinical cure (72.3% vs 67.8%) Imipenem 
had a clinical cure rate of 72.6% , but an additional cost of $229,152.1/cure. Median 
hospital LOS and mechanical ventilation were signiﬁcantly shorter with doripenem 
than imipenem (22 vs 27 days; P  0.010 and 7 vs 10 days; P  0.034). One-way sen-
sitivity analysis shows that the model is sensitive unitary cost of ICU and MV days 
and clinical cure. The probabilities to be cost-saving are Doripenem 90.1% versus 
Imipenem and 98% versus PT of 1,000 iterations in SPA. CONCLUSIONS: The uti-
lization of Doripenem as a ﬁrst-line therapy in adult patients with VAP is a cost-effec-
tive health intervention and results in considerable savings, compared with imipenem 
and piperazilina-tazobactam due to a signiﬁcantly reduced LOS in the ICU units.
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OBJECTIVES: To determine the most cost-effective alternative for inﬂuenza preven-
tion in Mexican elderly population in a pandemic case scenario. METHODS: A cost-
effectiveness study was performed with Mexican Public Health Institution perspective 
comparing the use of MF59-adjuvanted vaccine (MF59), split vaccine (SPL) and a No 
Vaccination Program Alternative (NOVA). A systematic review of literature was 
designed in order to evaluate the effectiveness of MF59 and SPL measured as hemag-
glutination-inhibition antibody titers against A/H1N1 strain, and to calculate the 
inﬂuenza incidence in a pandemic case scenario. A cost matrix was calculated consider-
ing vaccines, vaccination program, medical visits, inﬂuenza and inﬂuenza related 
complications treatment, hospitalization and intensive care unit cost. Different propor-
tions of patients with inﬂuenza were considered to determine complications related to 
the disease. Use of resources for complication treatment was assumed to be the same 
for every alternative evaluated. A decision tree was designed to simulate the use of 
resources. Results were evaluated with incremental analysis and sensitivity analysis 
of the most uncertain variables (inﬂuenza incidence, vaccine effectiveness, percentage 
of patients developing complications related to inﬂuenza) in order to establish robust-
ness of the study. RESULTS: The use of MF59 represents the lowest cost per patient 
avoiding inﬂuenza or complications related to inﬂuenza when compared with the use 
of SPL or NOVA (MF59: US$25.17; SPL: US$40.50; NOVA: US$127.27) due to 
reduced institutional expenses. The ICER shows that MF59 is a dominant alternative 
in prevention of inﬂuenza and its complications while the sensitivity analysis exhibits 
robustness for the base study. CONCLUSIONS: MF59 is the most cost-effective 
alternative in inﬂuenza prevention for elderly population when a pandemic case sce-
nario in Mexico is simulated. The use of MF59 represents savings estimated in 
US$15.32 and US$102.10 per patient avoiding inﬂuenza when compared to SPL and 
NOVA, respectively.
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OBJECTIVES: In mid 2001 the German Standing Vaccination Committee (STIKO) 
issued a vaccination recommendation for children at risk for pneumococcal diseases. 
This was expanded to all children under the age of two in 2006. In 2009 higher valent 
pneumococcal conjugate vaccines (PCV) will enter the German market. Aim of this 
study is to evaluate cost-effectiveness ratios in children compared to the current stan-
dard immunization (PCV7) in Germany. METHODS: A markov model compares in 
a steady state the historical epidemiological situation (without vaccination) with exist-
ing and upcoming PCV. For all vaccines incidence and cost of pneumococcal infections 
for children (meningitis; bacteraemia; pneumonia and AOM) is considered. Addition-
ally herd immunity effects for adults based on published data are included. In the base 
case the underlying vaccination regime was 31 with a vaccine uptake of 90%. 
RESULTS: In the base case PCV7, PCV10 and PCV13 reduce IPD cases on a popula-
tion level by 4593, 5305, and 6092, respectively. If herd immunity in the unvaccinated 
population is considered, all three PCV are cost-saving. A general vaccination with 
PCV13 dominates the 10- and 7-valent PCV. The validated effect of PCV on naso-
pharyngeal carriage results in herd immunity in non-vaccinated populations. Depend-
ing on vaccine uptake, this effect helps PCV13 to prevent costs of a1.40 (90% uptake) 
and a1.70 (80% uptake) for every Euro spent on vaccination. In sensitivity analyses 
the results were robust to variation of input variables. CONCLUSIONS: Compared 
to other existing PCV, PCV13 is a dominant cost-effective option to prevent pneumo-
coccal diseases. Not only from a medical and epidemiological point of view, but also 
from a health-economic perspective an immediate change from PCV7 to PCV13 
should be considered.
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OBJECTIVES: Seven-valent pneumococcal conjugate vaccine (PCV7) has demon-
strated dramatic public health impact and is considered highly cost-effective. Introduc-
tion of two new pneumococcal conjugate vaccines, 10-valent (PCV10) which is 
conjugated to protein-D, tetanus and diphtheria toxoids and 13-valent (PCV13) which 
is conjugated to CRM197 similar to PCV7, provides coverage to an additional 3 and 
6 serotypes respectively, which is likely to result in further reduction in pneumococcal 
disease. We examined the incremental public health impact and cost-effectiveness of 
two new vaccines compared to PCV7 in Canada. METHODS: A decision-analytic 
model (payer perspective) was developed to estimate impact of PCV13 and PCV10 
vs. PCV7 on invasive pneumococcal disease (IPD), pneumonia, and acute otitis media 
(AOM). We used an epidemiological approach to track serotype speciﬁc incidence, 
disease sequelae, death, and costs. Incidence, disease sequelae, indirect effects, utilities, 
and mortality data were obtained from surveillance systems in the province of Alberta, 
national vital statistics and published literature. Direct effects for PCV13 serotypes 
were assumed similar to those for PCV7 serotypes, whereas PCV10 was assumed to 
be less effective due to lower immunogenicity for the seven common serotypes. A 4-
dose schedule and parity pricing were assumed. RESULTS: When indirect effects due 
to herd immunity were considered for PCV7, PCV7 resulted in less costs and greater 
beneﬁts than PCV10. In the absence of indirect effects, the ICER for PCV10 vs. PCV7 
was $771,938 per QALY. PCV13 was cost saving compared to PCV7, whether indi-
rect effects or direct effects alone were considered. Through direct effects, PCV13 
pediatric vaccination would reduce 60% of IPD in vaccinated children. CONCLU-
SIONS: PCV7 is estimated to be cost saving compared to PCV10. The broader sero-
type coverage of PCV13 would provide additional protection against pneumococcal 
disease and PCV13 is expected to be cost saving.
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OBJECTIVES: To evaluate the cost-effectiveness of micafungin compared to caspo-
fungin in the treatment of systemic Candida infections (SCIs) in Italy, including inva-
sive candidiasis and candidaemia. METHODS: Cost-effectiveness of both echinocandin 
antifungal drugs was estimated using decision analysis. Response to treatment, 
resource utilisation, and costs in the model were derived from a phase 3, head-to-head 
comparative trial. The model includes only data directly related to the treatment of 
the systemic Candida infection over the study duration (a maximum period of 14 
weeks). Transition probabilities were calculated based on the efﬁcacy results from the 
clinical trial. The model’s effectiveness outcome is surviving patients who are success-
fully treated, based on the absence of signs and symptoms, radiographic abnormalities, 
and culture/histologic evidence associated with the fungal infection. In addition, sub-
group analyses were performed to identify cost-effectiveness in several speciﬁc patient 
groups. RESULTS: The total medical treatment costs for the micafungin group were 
a30,758 , which is similar to the total costs for the caspofungin group (a31,923). In 
the micafungin arm 60% of the patients and in the caspofungin arm 58% of the 
patients were successfully treated and alive. Cost-effectiveness ratio of micafungin was 
a51,558, and of caspofungin a55,489 per successfully treated patient. Because the 
costs are lower and the effectiveness is higher for micafungin in comparison with 
caspofungin, micafungin is more cost-effective than caspofungin. Probabilistic sensitiv-
ity and subgroup analysis show that although the difference cannot be considered 
signiﬁcant, due to a large variance, micafungin was the most cost-effective option in 
all subgroup analyses except one. CONCLUSIONS: Costs and effects of micafungin 
compare favourably to those of caspofungin in the treatment of systemic Candida 
infections in Italy. Sensitivity analysis showed that despite the uncertainty in cost-
effectiveness ratio this result is robust. Subgroup analyses showed similar results.
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OBJECTIVES: Pertussis is a highly contagious respiratory disease. Despite an effective 
childhood immunization programme the pertussis incidence among infants remains 
high. As parents are the main transmission vector to infants, their immunization 
